Johnson & Johnson receives positive CHMP opinion for
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of...
Source: globenewswire.com
Page 2 - Randomized Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Randomized Phase Today - Breaking & Trending Today
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking ...
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study
Source: eagletribune.com
Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer -April 08, 2024 at 04:52 pm EDT
Public neoantigen: repertoire4-5 Driver: Truncal: ...
Source: marketscreener.com
Concomitant Azoles Does Not Affect Clinical Outcomes With Ruxolitinib in Acute GVHD
Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.
Source: onclive.com
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical...
Source: marketscreener.com